Market Overview

UPDATE: Credit Suisse Upgrades Ironwood Pharmaceuticals to Outperform on Positive Linzess Survey

Share:
Related IRWD
Watch These 7 Huge Put Purchases In Friday Trade
Benzinga's Option Alert Recap From August 3

Credit Suisse upgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Neutral to Outperform and raised the price target from $15.00 to $24.00.

Credit Suisse analyst Catherine Arnold commented, "CS proprietary market research survey with ~100 physicians implies greater demand via both category expansion and competitive market share. Respondents include 55% gastroenterologists and 45% PCPs, ~70% who were early Linzess users, and all with brand awareness."

Ironwood Pharmaceuticals closed at $17.68 on Thursday.

Latest Ratings for IRWD

DateFirmActionFromTo
Jul 2017JP MorganDowngradesOverweightNeutral
May 2017Wells FargoInitiates Coverage OnOutperform
Aug 2016JP MorganMaintainsOverweight

View More Analyst Ratings for IRWD
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Analyst Ratings

 

Related Articles (IRWD)

View Comments and Join the Discussion!

Partner Center